S-1/A: CXApp Files Amendment No. 2 to Form S-1 Registration Statement, Eyes Resale of Shares and Warrants
S-1/A Filing
CXApp Inc. files an amendment to its Form S-1 registration statement, paving the way for the resale of existing shares and warrants by selling securityholders.
Summary
- CXApp Inc. has filed Amendment No. 2 to its Form S-1 registration statement with the SEC.
- The filing pertains to the resale of up to 10,026,776 shares of common stock by selling securityholders.
- It also covers the resale of up to 10,280,000 private placement warrants and the issuance of up to 24,080,000 shares of common stock upon exercise of warrants.
- The selling securityholders may sell their shares and warrants through various methods, including ordinary brokerage transactions, underwritten offerings, and privately negotiated transactions.
- CXApp will not receive any proceeds from the resale of these securities by the selling securityholders.
- The company's common stock trades on the Nasdaq Capital Market under the ticker symbol CXAI, and its warrants trade under CXAIW.
- The closing sale price of CXApp's common stock on October 1, 2024, was $1.59 per share, and the closing price of its warrants was $0.24 per warrant.
Sentiment
Score: 4
Explanation: The document is largely factual and related to a registration statement. The potential for downward pressure on the stock price and the company's history of operating losses temper the sentiment.
Negatives
- The resale of a significant number of shares could put downward pressure on the stock price.
- The exercise price of warrants may be higher than the prevailing market price, potentially leading to no cash proceeds for CXApp.
- The shares being registered for resale were purchased by selling securityholders at prices considerably below the current market price, which may impact market perception of the stock's value.
Risks
- The market price of CXApp's common stock and warrants may be volatile.
- The company has a history of operating losses and may need additional financing.
- Failure to adequately protect intellectual property rights could harm operations.
- The company relies on a limited number of key customers.
- The company may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
Future Outlook
The document does not provide specific forward-looking statements or guidance, but it does mention the potential for the company to receive proceeds from the exercise of warrants, which is contingent upon the stock price.
Industry Context
The document does not provide specific industry context.
Stakeholder Impact
- The resale of shares could impact the stock price, affecting current shareholders.
- The potential for the company to receive proceeds from warrant exercises could benefit the company's financial position.
Key Dates
| Date | Description |
|---|---|
| 2020-12-14 | Date of the Registration Rights Agreement. |
| 2020-12-14 | Date of the Warrant Agreement. |
| 2020-12-17 | KINS initial public offering was consummated. |
| 2022-09-25 | Date of the Merger Agreement. |
| 2023-03-14 | Closing date of the Merger. |
| 2023-03-15 | Trading of CXAI common stock and CXAIW warrants began on Nasdaq. |
| 2023-04-13 | Warrants became exercisable. |
| 2024-05-22 | Date of the Securities Purchase Agreement with Streeterville Capital, LLC. |
| 2024-10-01 | Closing sale price of CXAI common stock was $1.59 and CXAIW warrants was $0.24. |
Keywords
S-1, registration statement, resale, common stock, warrants, selling securityholders, CXApp, CXAI, CXAIW, private placement, public offering
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.